Abstract
Cellular response to oestradiol stimuli is mediated both by oestrogen receptor (ER) binding to oestrogen response elements (EREs) and by non-nuclear actions like activation of mitogen-activated protein kinase (MAPK) signal transduction. Therefore, oestradiol stimuli might be able to interfere with the action of antitumoral substances directed against receptor tyrosine kinase signalling. We investigated the effect of oestradiol on the inhibition of HER2 signalling by trastuzumab (Herceptin) in two human endometrial adenocarcinoma cell lines. Activation of the extracellular signal-regulated kinase (ERK-1/2), a major mediator of HER2 signalling, was measured by means of western blotting experiments and ERE activation was determined in transient reporter-gene assays. In endometrial Ishikawa and HEC-1A adenocarcinoma cells, HER2 signalling was inhibited by trastuzumab only in the absence of oestradiol. We were able to demonstrate that oestradiol counteracted the inhibitory effects of trastuzumab by rapid phosphorylation of ERK-1/2, a kinase downstream of the HER2 receptor. The pure anti-oestrogen ICI 182,780 was able to restore both the trastuzumab-triggered inhibition of the ERK-1/2 pathway and the antiproliferative action of this ...Continue Reading
References
Jan 1, 1996·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·J FujimotoT Tamaya
Aug 1, 1993·Molecular and Cellular Biology·D L CharestS L Pelech
Apr 1, 1994·The Journal of Steroid Biochemistry and Molecular Biology·L J Murphy
Nov 15, 1995·Cancer·A Berchuck, J Boyd
Jan 1, 1996·Breast Cancer Research and Treatment·R LupuC Tang
Feb 19, 1998·Oncogene·R C O'Hagan, J A Hassell
Jan 14, 1999·Oncology·D NiederacherM W Beckmann
Apr 14, 1999·Proceedings of the National Academy of Sciences of the United States of America·T Improta-BrearsD P McDonnell
Apr 15, 1999·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·C D RolitskyT H Niemann
Sep 30, 1999·Nature Medicine·P Collins, C Webb
Nov 11, 1999·Oncogene·Z AguilarD J Slamon
Sep 21, 2000·International Journal of Oncology·M M HijaziR Lupu
Oct 24, 2000·Molecular Endocrinology·E J FilardoA R Frackelton
Dec 6, 2000·The Journal of Biological Chemistry·A H TalukderR Kumar
Citations
Aug 17, 2010·Oncogene·L E Arias-RomeroJ Chernoff
Jan 21, 2016·Oncology Letters·Jiafeng LuQinyu Ge
Nov 7, 2012·The Breast : Official Journal of the European Society of Mastology·Aggelos LaliotisEfstathios N Stathopoulos
Jul 17, 2009·Journal of Cellular and Molecular Medicine·Susanne HippKarl-Friedrich Becker
Sep 12, 2006·Gynecologic Oncology·Kirsten EjskjaerOle Mogensen
Jul 22, 2008·Medicinal Research Reviews·George G ChenGary Mk Tse
Nov 30, 2006·The Journal of Pathology·K-F BeckerH Höfler
Sep 1, 2007·Analytica Chimica Acta·Tetsuya Haruyama
Mar 29, 2006·The Journal of Steroid Biochemistry and Molecular Biology·Rui-Xia GuoJian-Min Tang
Oct 31, 2017·Cancer Biomarkers : Section a of Disease Markers·Lan LuoLiang Tang
Dec 27, 2018·DNA and Cell Biology·Yi SuLianzhi Yu
Jul 1, 2010·British Journal of Cancer·J-P DelordB C Allal
Oct 15, 2005·Endocrinology·Whitney W WoodmanseeWilliam M Wood
Dec 8, 2017·Scandinavian Journal of Public Health·Maria KristiansenCarsten Hendriksen
Mar 25, 2004·The Journal of Biological Chemistry·Geraldine A FinlayDaniel J Noonan
Feb 2, 2010·Endocrinology·Vijay PandeyPeter E Lobie
Dec 13, 2005·Endocrinology·Filippo AcconciaRakesh Kumar
Aug 7, 2017·Theriogenology·Chenchen WuBaoyu Zhao
Oct 2, 2021·BMC Bioinformatics·Giuseppe Agapito, Mario Cannataro